Skip to content

Efficacy and safety of topiramate and flunarizine in the prevention of migraine

Efficacy and safety of topiramate and flunarizine in the prevention of migraine

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063095
Enrollment
Unknown
Registered
2022-08-30
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

Conrol group:Flunarizine

Sponsors

Sichuan Panzhihua Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-65 years; 2. Headaches caused by primary diseases such as intracranial organic lesions and anemia have been ruled out by head CT or MRI scans and laboratory tests; 3. The patient's quality of life, work and studies are impaired (need to be judged by the patient himself); 4. The attack frequency is more than 4 times per month; 5. For 2 consecutive months, use the acute phase treatment more than 6-8 times a month; 6. According to visual linear analogue scale (visual linear analogue scale, VAS) digital grading method, headache degree >= 4 points; 7. Patients and family members are aware of this study, sign the informed consent form, and have been reviewed and approved by the ethics committee of the hospital.

Exclusion criteria

Exclusion criteria: 1. Patients with symptoms of Parkinson's disease or other extrapyramidal diseases; 2. Pregnant and lactating women; 3. Hypersensitivity to active ingredients; 4. Patients with severe heart, lung, liver and kidney dysfunction or other serious systemic diseases; 5. Patients with high blood pressure or low blood pressure; 6. Patients with a history of mental illness; 7. Patients with secondary headache hidden dangers (systemic diseases: cold and fever; ENT diseases; toothache, sinusitis, otitis media; brain diseases: cerebral hemorrhage, subarachnoid hemorrhage, encephalitis, meningitis, brain tumors , cerebral infarction, craniocerebral injury; primary headache: trigeminal neuralgia, occipital neuralgia, cluster headache, tension headache; others: uremia, hypoglycemia, anemia, dysmenorrhea).

Design outcomes

Primary

MeasureTime frame
Headache attack frequency (times/month);Degree of headache;Headache duration;

Countries

China

Contacts

Public ContactZhang Yuehui

34 Yikang Street, Middle Section of Panzhihua Avenue, East District, Panzhihua

1784771298@qq.com+86 18281204248

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026